|
【结 构 式】 
|
【分子编号】65168 【品名】(8S,11S,17S,20S,23S,26S,29S)-17,23-dibenzyl-26-[(1R)-1-hydroxyethyl]-11,29-diisobutyl-20-isopropyl-8-[(1S)-1-methylpropyl]-1-(3-nitro-4-{[(2S,3R,4S,5S,6S)-3,4,5-trihydroxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl]oxy}phenyl)-3,6,9,12,15,18,21,24, 【CA登记号】 |
【 分 子 式 】C64H90N10O22 【 分 子 量 】1351.4728 【元素组成】C 56.88% H 6.71% N 10.36% O 26.04% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(XXIV)Condensation of pentafluorophenyl ester (VI) with octapeptide (XXIII) gives rise to the nonapeptide conjugate (XXIV). The methyl ester group of (XXIV) is finally hydrolyzed by means of barium hydroxide in MeOH to produce the target compound.
| 【1】 Rawale, S.; Hrihorczuk, L.M.; Wei, W.-Z.; Zemlicka, J.; Synthesis and biological activity of the prodrug of class I major histocompatibility peptide GILGFVFTL activated by Beta-glucuronidase. J Med Chem 2002, 45, 4, 937. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 65157 | methyl (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(2-nitro-4-{[({[2-oxo-2-(2,3,4,5,6-pentafluorophenoxy)ethyl]amino}carbonyl)oxy]methyl}phenoxy)tetrahydro-2H-pyran-2-carboxylate | C23H19F5N2O13 | 详情 | 详情 | |
| (XXIII) | 65164 | (2S,5S,8S,11S,14S,20S,23S,24S)-23-amino-8,14-dibenzyl-5-[(1R)-1-hydroxyethyl]-2,20-diisobutyl-11-isopropyl-24-methyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazahexacosan-1-oic acid | C47H72N8O10 | 详情 | 详情 | |
| (XXIV) | 65168 | (8S,11S,17S,20S,23S,26S,29S)-17,23-dibenzyl-26-[(1R)-1-hydroxyethyl]-11,29-diisobutyl-20-isopropyl-8-[(1S)-1-methylpropyl]-1-(3-nitro-4-{[(2S,3R,4S,5S,6S)-3,4,5-trihydroxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl]oxy}phenyl)-3,6,9,12,15,18,21,24, | C64H90N10O22 | 详情 | 详情 |
Extended Information